Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alcohol and breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Alcohol and breast cancer. Displaying page 1 of 1.
    EudraCT Number: 2018-002406-32 Sponsor Protocol Number: 2018-0601 Start Date*: 2018-11-19
    Sponsor Name:Institut de Cancérologie Lucien Neuwirth
    Full Title: HOMEORAD : Randomized Phase III Trial Evaluating Homeopathic Radium Bromatum® Impact on the Prevention and Treatment of Radiodermites in Breast Cancer Patients
    Medical condition: Indication of curative radiotherapy after conservative breast cancer surgery. Accepted scheme of radiotherapy: 50 Gy (main) + 16 Gy on the tumoral bed (supplement of dose).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001972-12 Sponsor Protocol Number: AA1817 Start Date*: 2019-09-13
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: A phase 1b/2 open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer
    Medical condition: in phase 1b part: advanced and/or treatment refractory solid malignancies in phase 2 part : advanced or metastatic HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000864-94 Sponsor Protocol Number: EORTC protocol 10054 Start Date*: 2007-01-15
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase I-II study of lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer.
    Medical condition: Locally advanced/inflammatory or large operable brest cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2012-002460-27 Sponsor Protocol Number: 1.1 Start Date*: 2013-02-04
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Preoperative skin preparation to lower surgical site infection in breast cancer surgery: Povidone – iodine 10% aqueous solution versus 2%chlorhexidine in 70% isopropyl alcohol (ChloraPrep, Cardina...
    Medical condition: PATIENTS SCHEDULED FOR SURGERY
    Disease: Version SOC Term Classification Code Term Level
    15.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    15.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003065-17 Sponsor Protocol Number: CRAD001Y24135 Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally ad...
    Medical condition: Estrogen receptor positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) NL (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-000172-19 Sponsor Protocol Number: DPAM Start Date*: 2022-12-09
    Sponsor Name:Consorci Sanitari Integral
    Full Title: Effect of 0.5% local lidocaine injection on the prevention of acute postoperative pain associated with breast surgery
    Medical condition: The reduction of acute postoperatory pain in female patients diagnosed with breast cancer and undergoing surgical treatment is investigated.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000134-34 Sponsor Protocol Number: TEAM(B115UCS2019) Start Date*: 2021-05-24
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial.
    Medical condition: Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000418-23 Sponsor Protocol Number: AGO/2015/002 Start Date*: 2015-12-18
    Sponsor Name:Ghent University Hospital
    Full Title: Intraoperative intraperitoneal chemoperfusion to treat peritoneal minimal residual disease in stage III ovarian cancer: a randomized phase II trial.
    Medical condition: stage III ovarian cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001688-20 Sponsor Protocol Number: AGO/2017/003 Start Date*: 2017-08-25
    Sponsor Name:Ghent University Hospital
    Full Title: INTRAPERITONEAL AEROSOLISATION OF ALBUMIN-STABILIZED PACLITAXEL NANOPARTICLES FOR PERITONEAL CARCINOMATOSIS – PHASE I/II STUDY PROTOCOL
    Medical condition: peritoneal carcinomatosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002093-12 Sponsor Protocol Number: 1506-STBSG Start Date*: 2017-07-04
    Sponsor Name:European Organisation for Research and Treatment of
    Full Title: A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastat...
    Medical condition: Metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) NL (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 07:14:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA